Sanofi's Actonel added indication for male osteoporosis.

Published: 2007-04-20 06:57:00
Updated: 2007-04-20 06:57:00
Sanofi-Aventis Korea announced that the KFDA recently approved an additional indication of Actonel (risedronate sodium) for the treatment of male osteoporosis.

Actonel is a derivative of the bisphonphonates for the treatment of osteoporosis to protect fractures of back bones or other sites wit...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.